COMMUNIQUÉS West-GlobeNewswire

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
24/03/2026
Launched VIZZ ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid [...]
Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence
24/03/2026
ARLINGTON, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated medical groups, collectively Privia Medical Group, has been named a recipient of the [...]
SK pharmteco and Prozomix Announce Strategic Collaboration to Enhance Biocatalysis Capabilities for Global Drug Manufacturing
24/03/2026
RANCHO CORDOVA, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- SK pharmteco , a leading global contract development and manufacturing organization (CDMO), and Prozomix , a pioneer in enzyme discovery and diversity, today [...]
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
24/03/2026
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and [...]
Applied StemCell and Cellipont Bioservices Partner to Offer a Seamless Path for iPSC-Derived Cell Therapy Development
24/03/2026
MILPITAS, Calif. and THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and [...]
SurvivorRx Expands Personalized Supplement Routines as Oncologists Raise Concerns About Supplement Safety for Cancer Survivors
24/03/2026
New oncology- and naturopath-informed supplement systems aim to simplify post-treatment wellness while addressing safety, dosing, and formulation challenges many survivors face JACKSONVILLE, Fla., March 24, 2026 (GLOBE [...]
San Juan Regional Medical Center Selects Full PerfectServe Platform for Enterprise Communication and Scheduling Overhaul
24/03/2026
Unique platform breadth, advanced capabilities, integrated patient-family communication, highly collaborative project team made PerfectServe the clear choice MIAMI and FARMINGTON, N.M., March 24, 2026 (GLOBE NEWSWIRE [...]
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
24/03/2026
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent KRAS [...]
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
24/03/2026
TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial [...]
Lace-Up Ankle Brace Support Gets Comfort Upgrade and Removable Side Stabilizers
24/03/2026
Lynden, WASHINGTON, March 24, 2026 (GLOBE NEWSWIRE) -- Z Athletics has announced an upcoming updated version of its flagship lace-up ankle brace, featuring upgraded comfort materials and new removable semi-rigid side [...]
Addgene and Plasmidsaurus Announce Strategic Partnership to Scale Sequencing for Leading Plasmid Repository
24/03/2026
Strategic partnership to ensure delivery of scalable, cost-effective, and reliable plasmid sequencing as Addgene’s repository expands WATERTOWN, Mass. and SAN FRANCISCO, March 24, 2026 (GLOBE NEWSWIRE) -- Addgene , an [...]
Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company’s Scientific Advisory Board
24/03/2026
-- Dr. Ashworth Brings Decades of Scientific and Clinical Experience Translating Synthetic Lethality Discoveries into Precision Cancer Therapies -- SOUTH SAN FRANCISCO, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- [...]
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
24/03/2026
H.R. 7091 Supports Development of Investigational Treatments for Alcohol Use Disorder and Aligns with Evolving Federal Recovery Standards GLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( [...]
Callio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in Advanced HER2-Expressing Solid Tumors
24/03/2026
Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors CLIO-8221 is the first program from Callio Therapeutics [...]
CenTrak Advances Its RTLS Platform Through Enhanced Healthcare Integrations
24/03/2026
CenTrak receives Epic Toolbox designation and Rauland® VIP Program validation, highlighting interoperable, scalable solutions that streamline clinical workflows and system connectivity NEWTOWN, Pa., March 24, 2026 ( [...]
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
24/03/2026
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, [...]
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
24/03/2026
AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary [...]
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
24/03/2026
Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of [...]
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
24/03/2026
RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]

Pages